Eagle Global Advisors LLC Decreases Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Eagle Global Advisors LLC lessened its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 8.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 130,667 shares of the company’s stock after selling 11,466 shares during the period. Eagle Global Advisors LLC’s holdings in Merck & Co., Inc. were worth $14,245,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Wellington Management Group LLP boosted its stake in Merck & Co., Inc. by 6.7% in the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock valued at $8,487,472,000 after acquiring an additional 5,196,914 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Merck & Co., Inc. by 14.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock worth $3,966,029,000 after buying an additional 4,731,152 shares during the last quarter. Northern Trust Corp increased its position in Merck & Co., Inc. by 4.1% during the 3rd quarter. Northern Trust Corp now owns 29,859,623 shares of the company’s stock valued at $3,074,048,000 after buying an additional 1,186,842 shares in the last quarter. Norges Bank purchased a new stake in Merck & Co., Inc. in the fourth quarter valued at about $3,108,366,000. Finally, Fisher Asset Management LLC boosted its holdings in Merck & Co., Inc. by 1.7% in the fourth quarter. Fisher Asset Management LLC now owns 13,566,968 shares of the company’s stock worth $1,479,071,000 after acquiring an additional 228,578 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

Shares of MRK stock traded down $1.61 during trading hours on Friday, hitting $129.48. 5,982,915 shares of the company’s stock were exchanged, compared to its average volume of 7,980,284. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10. The firm has a market cap of $327.95 billion, a P/E ratio of 145.67, a P/E/G ratio of 1.68 and a beta of 0.39. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. The firm has a 50 day moving average of $127.99 and a two-hundred day moving average of $119.40.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.94 by $0.13. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.40 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 8.69 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Societe Generale lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective for the company. in a research report on Monday, March 11th. Barclays raised their target price on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $135.00 price objective on shares of Merck & Co., Inc. in a research note on Thursday, April 18th. Finally, UBS Group upped their target price on Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $131.33.

Get Our Latest Analysis on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.